Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Asset Utilization Ratio (2021 - 2025)

Historic Asset Utilization Ratio for Lyell Immunopharma (LYEL) over the last 5 years, with Q3 2025 value amounting to 0.0.

  • Lyell Immunopharma's Asset Utilization Ratio rose 444.59% to 0.0 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.0, marking a year-over-year increase of 444.59%. This contributed to the annual value of 0.0 for FY2024, which is 3618.53% down from last year.
  • As of Q3 2025, Lyell Immunopharma's Asset Utilization Ratio stood at 0.0, which was up 444.59% from 0.0 recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Asset Utilization Ratio high stood at 0.09 for Q1 2023, and its period low was 0.0 during Q2 2024.
  • Over the past 5 years, Lyell Immunopharma's median Asset Utilization Ratio value was 0.01 (recorded in 2022), while the average stood at 0.02.
  • Its Asset Utilization Ratio has fluctuated over the past 5 years, first surged by 106308.27% in 2023, then tumbled by 9989.83% in 2024.
  • Over the past 5 years, Lyell Immunopharma's Asset Utilization Ratio (Quarter) stood at 0.01 in 2021, then soared by 865.78% to 0.09 in 2022, then tumbled by 99.81% to 0.0 in 2023, then plummeted by 34.69% to 0.0 in 2024, then decreased by 5.96% to 0.0 in 2025.
  • Its Asset Utilization Ratio was 0.0 in Q3 2025, compared to 0.0 in Q2 2025 and 0.0 in Q1 2025.